Bio-Techne enforces intellectual property for
gold standard RNAscope® ISH technology in spatial biology
research and clinical applications.
MINNEAPOLIS, April 23,
2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:
TECH), a global life sciences company providing innovative tools
and bioactive reagents for the research and clinical diagnostic
communities, today announced that it has taken legal action in
the Unified Patent Court in Europe
to halt the infringement of its patented RNAscope® ISH technology
by Molecular Instruments, Inc.
Bio-Techne, under its Advanced Cell Diagnostics (ACD) brand,
owns patents covering numerous features of its RNAscope technology.
Bio-Techne is a pioneer in spatial biology, with its broad
portfolio of over 50,000 unique RNAscope in situ
hybridization (ISH) probes across over 400 species offering its
biopharma and academic customers best-in-class single-molecule
sensitivity with unrivaled specificity at subcellular resolution.
RNAscope is the most referenced technology in the industry, with
its rapidly growing portfolio of peer-reviewed publications
recently surpassing 10,000.
In its lawsuit filed in the Unified Patent Court (a pan-European
forum for resolving patent disputes), in the Netherlands Local Division of the Court of
First Instance in The Hague,
Bio-Techne alleges that Molecular Instruments' HCR 3.0
technology infringes ACD's European Patents 1,910,572 and
2,500,439. The lawsuit seeks damages and injunctive relief
requiring Molecular Instruments to stop infringing ACD's patents in
key European markets.
"Bio-Techne has made substantial investments to become the
global leader in the rapidly growing spatial biology industry,
including the development and application of its RNAscope
technology as well as the acquisition of Lunaphore, which added the
fully automated, high-throughput, hyperplex COMET platform to the
portfolio," said Kim Kelderman, President and Chief Executive
Officer of Bio-Techne. "We will continue to diligently monitor the
spatial biology industry, as well as all of the areas where we
operate, for violators of our intellectual property and vigorously
defend our position against any potential offenders."
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-441
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-files-patent-infringement-lawsuit-against-molecular-instruments-302124152.html
SOURCE Bio-Techne Corporation